Show simple item record

 
dc.contributorVall d'Hebron Barcelona Hospital Campus
dc.contributor.authorGarcía-Montolio, Marc
dc.contributor.authorBallaré, Cecilia
dc.contributor.authorBlanco, Enrique
dc.contributor.authorGutiérrez, Arantxa
dc.contributor.authorAranda, Sergi
dc.contributor.authorGomez Moruno, Antonio
dc.date.accessioned2021-12-16T12:38:01Z
dc.date.available2021-12-16T12:38:01Z
dc.date.issued2021-04-29
dc.identifier.citationGarcía-Montolio M, Ballaré C, Blanco E, Gutiérrez A, Aranda S, Gómez A, et al. Polycomb Factor PHF19 Controls Cell Growth and Differentiation Toward Erythroid Pathway in Chronic Myeloid Leukemia Cells. Front Cell Dev Biol. 2021 Apr 29;9:665201.
dc.identifier.issn2296-634X
dc.identifier.urihttps://hdl.handle.net/11351/6701
dc.descriptionChronic myeloid leukemia; Erythroid differentiation; Polycomb
dc.description.abstractPolycomb group (PcG) of proteins are a group of highly conserved epigenetic regulators involved in many biological functions, such as embryonic development, cell proliferation, and adult stem cell determination. PHD finger protein 19 (PHF19) is an associated factor of Polycomb repressor complex 2 (PRC2), often upregulated in human cancers. In particular, myeloid leukemia cell lines show increased levels of PHF19, yet little is known about its function. Here, we have characterized the role of PHF19 in myeloid leukemia cells. We demonstrated that PHF19 depletion decreases cell proliferation and promotes chronic myeloid leukemia (CML) differentiation. Mechanistically, we have shown how PHF19 regulates the proliferation of CML through a direct regulation of the cell cycle inhibitor p21. Furthermore, we observed that MTF2, a PHF19 homolog, partially compensates for PHF19 depletion in a subset of target genes, instructing specific erythroid differentiation. Taken together, our results show that PHF19 is a key transcriptional regulator for cell fate determination and could be a potential therapeutic target for myeloid leukemia treatment.
dc.language.isoeng
dc.publisherFrontiers Media
dc.relation.ispartofseriesFrontiers in Cell and Developmental Biology;9
dc.rightsAttribution 4.0 International
dc.rights.urihttp://creativecommons.org/licenses/by/4.0/
dc.sourceScientia
dc.subjectLeucèmia mieloide crònica - Tractament
dc.subjectRegulació genètica
dc.subject.meshLeukemia, Myeloid
dc.subject.mesh/therapy
dc.subject.meshGene Expression Regulation, Neoplastic
dc.titlePolycomb Factor PHF19 Controls Cell Growth and Differentiation Toward Erythroid Pathway in Chronic Myeloid Leukemia Cells
dc.typeinfo:eu-repo/semantics/article
dc.identifier.doi10.3389/fcell.2021.655201
dc.subject.decsleucemia mieloide
dc.subject.decs/terapia
dc.subject.decsregulación de la expresión génica neoplásica
dc.relation.publishversionhttps://doi.org/10.3389/fcell.2021.655201
dc.type.versioninfo:eu-repo/semantics/publishedVersion
dc.audienceProfessionals
dc.contributor.organismesInstitut Català de la Salut
dc.contributor.authoraffiliation[García-Montolio M, Ballaré C, Blanco E, Gutiérrez A, Aranda S] Epigenetics Events in Cancer Laboratory, Centre for Genomic Regulation (CRG), Barcelona Institute of Science and Technology, Barcelona, Spain. [Gómez A] Grup de Recerca en Reumatologia, Servei de Reumatologia, Vall d’Hebron Institut de Recerca (VHIR), Barcelona, Spain
dc.identifier.pmid33996816
dc.identifier.wos000649663800001
dc.relation.projectidinfo:eu-repo/grantAgreement/ES/PE2013-2016/BFU2016-75008-P
dc.relation.projectidinfo:eu-repo/grantAgreement/ES/PE2017-2020/PID2019-108322GB-100
dc.relation.projectidinfo:eu-repo/grantAgreement/ES/PE2017-2020/PI19%2F01814
dc.rights.accessrightsinfo:eu-repo/semantics/openAccess


Files in this item

Thumbnail

This item appears in the following Collection(s)

Show simple item record